Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ISRCTN88772403) titled '5G: A next generation agile genomically guided glioma modular platform for proof-of-concept molecular hypothesis testing in patients with malignant brain tumours' on Feb. 24.
Study Type: Interventional
Study Design:
- (Efficacy, Safety)
Primary Sponsor: Institute of Cancer Research
Condition:
Glioblastoma
Cancer
Intervention:
The clinical trial will be divided into two parts: Phase 1b (proof of concept of hypothesis-driven biomarker-guided therapies) and Phase 2 (preliminary efficacy testing).
This is a study within 5G: A Next Generation AGile Genomically Guided Glioma Modular Platform for proof-of-concept...